{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:51:27Z","timestamp":1787698287992,"version":"build-2784847793"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Advanced Program of The Affiliated Hospital of Xuzhou Medical University","award":["PYJH2024314"],"award-info":[{"award-number":["PYJH2024314"]}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01812-9","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:01:03Z","timestamp":1754337663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aducanumab binds high molecular weight soluble A\u03b2 oligomers and restores intracellular calcium levels"],"prefix":"10.1186","volume":"17","author":[{"given":"Lu","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri H.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bussiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Bacskai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia V.","family":"Kastanenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"1","key":"1812_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14336\/AD.2021.0616","volume":"13","author":"BO Botchway","year":"2022","unstructured":"Botchway BO, Okoye FC, Chen Y, Arthur WE, Fang M. Alzheimer disease: recent updates on apolipoprotein E and gut microbiome mediation of oxidative stress, and prospective interventional agents. Aging Dis. 2022;13(1):87\u2013102.","journal-title":"Aging Dis"},{"issue":"1","key":"1812_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7150\/thno.79535","volume":"13","author":"J Zhao","year":"2023","unstructured":"Zhao J, Huai J. Role of primary aging hallmarks in Alzheimer s disease. Theranostics. 2023;13(1):197\u2013230.","journal-title":"Theranostics"},{"issue":"2","key":"1812_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal DR, Walter J, Saido TC, Fandrich M. Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer\u2019s disease. Acta Neuropathol. 2015;129(2):167\u201382.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1812_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-017-0169-9","volume":"12","author":"M Arbel-Ornath","year":"2017","unstructured":"Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, Hou S, Lattarulo CR, Belcher AM, Shakerdge N, Trujillo PB, Muzikansky A, Betensky RA, Hyman BT, Bacskai BJ. Soluble oligomeric amyloid-beta induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegener. 2017;12(1):27.","journal-title":"Mol Neurodegener"},{"key":"1812_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114596","volume":"162","author":"J Panes-Fernandez","year":"2023","unstructured":"Panes-Fernandez J, Godoy PA, Gavilan J, Ramirez-Molina O, Burgos CF, Marileo A, Flores-Nunez O, Castro PA, Moraga-Cid G, Yevenes GE, Munoz-Montesino C, Fuentealba J. TG2 promotes amyloid beta aggregates: impact on ER-mitochondria crosstalk, calcium homeostasis and synaptic function in Alzheimer\u2019s disease. Biomed Pharmacother. 2023;162: 114596.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1812_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-6-20","volume":"6","author":"A Takamura","year":"2011","unstructured":"Takamura A, Okamoto Y, Kawarabayashi T, Yokoseki T, Shibata M, Mouri A, Nabeshima T, Sun H, Abe K, Urisu T, Yamamoto N, Shoji M, Yanagisawa K, Michikawa M, Matsubara E. Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer\u2019s disease model mouse. Mol Neurodegener. 2011;6(1): 20.","journal-title":"Mol Neurodegener"},{"issue":"7618","key":"1812_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"1","key":"1812_CR8","doi-asserted-by":"publisher","first-page":"31925","DOI":"10.52965\/001c.31925","volume":"10","author":"HW Haddad","year":"2022","unstructured":"Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer\u2019s Disease: A Comprehensive Review. Health Psychol Res. 2022;10(1):31925.","journal-title":"Health Psychol Res"},{"issue":"3","key":"1812_CR9","volume":"10","author":"HW Haddad","year":"2022","unstructured":"Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Poliwoda S, Kaye RJ, Murnane KS, Kaye AM, Kaye AD. Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer\u2019s disease: a comprehensive review. Health Psychol Res. 2022;10(3): 37023.","journal-title":"Health Psychol Res"},{"issue":"1","key":"1812_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40035-022-00333-x","volume":"11","author":"C Kong","year":"2022","unstructured":"Kong C, Yang EJ, Shin J, Park J, Kim SH, Park SW, Chang WS, Lee CH, Kim H, Kim HS, Chang JW. Enhanced delivery of a low dose of aducanumab via FUS in 5xFAD mice, an AD model. Transl Neurodegener. 2022;11(1):57.","journal-title":"Transl Neurodegener"},{"key":"1812_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jconrel.2023.12.003","volume":"365","author":"D Su","year":"2024","unstructured":"Su D, Chen Z, An X, Yang J, Yang J, Wang X, Qu Y, Gong C, Chai Y, Liu X, Cheng W, Wang D, Wu Y, Ma J, Zhao X, Wang Q, Xu Y, Peng H, Ai J. Microrna-195 liposomes for therapy of Alzheimer\u2019s disease. J Control Release. 2024;365:583\u2013601.","journal-title":"J Control Release"},{"issue":"1","key":"1812_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JAD-200715","volume":"79","author":"J Bastrup","year":"2021","unstructured":"Bastrup J, Hansen KH, Poulsen TBG, Kastaniegaard K, Asuni AA, Christensen S, Belling D, Helboe L, Stensballe A, Volbracht C. Anti-Abeta antibody aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a transgenic mouse model of Alzheimer\u2019s disease. J Alzheimers Dis. 2021;79(1):249\u201365.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1812_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/psyg.12944","volume":"23","author":"A Rahman","year":"2023","unstructured":"Rahman A, Hossen MA, Chowdhury MF, Bari S, Tamanna N, Sultana SS, Haque SN, Al Masud A, Saif-Ur-Rahman KM. Aducanumab for the treatment of Alzheimer\u2019s disease: a systematic review. Psychogeriatrics. 2023;23(3):512\u201322.","journal-title":"Psychogeriatrics."},{"issue":"10","key":"1812_CR14","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","volume":"181","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Cavazzoni P. Approval of aducanumab for Alzheimer disease-the FDA\u2019s perspective. JAMA Intern Med. 2021;181(10):1276\u20138.","journal-title":"JAMA Intern Med"},{"issue":"50","key":"1812_CR15","doi-asserted-by":"publisher","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","volume":"36","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K, Bacskai BJ. Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci. 2016;36(50):12549\u201358.","journal-title":"J Neurosci"},{"issue":"2","key":"1812_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3233\/JAD-231387","volume":"99","author":"MR Miller","year":"2024","unstructured":"Miller MR, Lariviere L, Pagnier GJ, Aygar S, Wieckiewicz N, Maesako M, Bacskai BJ, Kastanenka KV. NB-02 protects neurons and astrocytes from oligomeric amyloid-beta-mediated damage. J Alzheimers Dis. 2024;99(2):477\u201383.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1812_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1751-1097.1993.tb09571.x","volume":"58","author":"H Szmacinski","year":"1993","unstructured":"Szmacinski H, Gryczynski I, Lakowicz JR. Calcium-dependent fluorescence lifetimes of Indo-1 for one- and two-photon excitation of fluorescence. Photochem Photobiol. 1993;58(3):341\u20135.","journal-title":"Photochem Photobiol"},{"issue":"1","key":"1812_CR18","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1038\/s41598-018-22979-2","volume":"8","author":"X Wang","year":"2018","unstructured":"Wang X, Kastanenka KV, Arbel-Ornath M, Commins C, Kuzuya A, Lariviere AJ, Krafft GA, Hefti F, Jerecic J, Bacskai BJ. An acute functional screen identifies an effective antibody targeting amyloid-beta oligomers based on calcium imaging. Sci Rep. 2018;8(1):4634.","journal-title":"Sci Rep"},{"issue":"6","key":"1812_CR19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.24272\/j.issn.2095-8137.2022.289","volume":"43","author":"ZY Chen","year":"2022","unstructured":"Chen ZY, Zhang Y. Animal models of Alzheimer\u2019s disease: applications, evaluation, and perspectives. Zool Res. 2022;43(6):1026\u201340.","journal-title":"Zool Res"},{"issue":"3","key":"1812_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbrc.2019.05.131","volume":"515","author":"N Izuo","year":"2019","unstructured":"Izuo N, Murakami K, Fujihara Y, Maeda M, Saito T, Saido TC, Irie K, Shimizu T. An App knock-in mouse inducing the formation of a toxic conformer of Abeta as a model for evaluating only oligomer-induced cognitive decline in Alzheimer\u2019s disease. Biochem Biophys Res Commun. 2019;515(3):462\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1812_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11671-6","volume":"7","author":"N Izuo","year":"2017","unstructured":"Izuo N, Kasahara C, Murakami K, Kume T, Maeda M, Irie K, Yokote K, Shimizu T. A toxic conformer of Abeta42 with a turn at 22\u201323 is a novel therapeutic target for Alzheimer\u2019s disease. Sci Rep. 2017;7(1): 11811.","journal-title":"Sci Rep"},{"issue":"1","key":"1812_CR22","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussiere T, Hamann S, Cameron TO, Weinreb PH. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci Rep. 2018;8(1):6412.","journal-title":"Sci Rep"},{"issue":"3","key":"1812_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/alzrt261","volume":"6","author":"H Feinberg","year":"2014","unstructured":"Feinberg H, Saldanha JW, Diep L, Goel A, Widom A, Veldman GM, Weis WI, Schenk D, Basi GS. Crystal structure reveals conservation of amyloid-beta conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res Ther. 2014;6(3):31.","journal-title":"Alzheimers Res Ther"},{"issue":"18","key":"1812_CR24","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","volume":"22","author":"BJ Bacskai","year":"2002","unstructured":"Bacskai BJ, Kajdasz ST, Mclellan ME, Games D, Seubert P, Schenk D, Hyman BT. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002;22(18):7873\u20138.","journal-title":"J Neurosci"},{"issue":"1","key":"1812_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01110-8","volume":"14","author":"RJ Bateman","year":"2022","unstructured":"Bateman RJ, Cummings J, Schobel S, Salloway S, Vellas B, Boada M, Black SE, Blennow K, Fontoura P, Klein G, Assuncao SS, Smith J, Doody RS. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1): 178.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1812_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49\u201369.","journal-title":"J Alzheimers Dis"},{"key":"1812_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.trci.2018.10.001","volume":"4","author":"BA Willis","year":"2018","unstructured":"Willis BA, Sundell K, Lachno DR, Ferguson-Sells LR, Case MG, Holdridge K, Demattos RB, Raskin J, Siemers ER, Dean RA. Central pharmacodynamic activity of solanezumab in mild Alzheimer\u2019s disease dementia. Alzheimers Dement (N Y). 2018;4:652\u201360.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"1812_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):311\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1812_CR29","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3390\/ijms13033038","volume":"13","author":"NE Pryor","year":"2012","unstructured":"Pryor NE, Moss MA, Hestekin CN. Unraveling the early events of amyloid-beta protein (Abeta) aggregation: techniques for the determination of Abeta aggregate size. Int J Mol Sci. 2012;13(3):3038\u201372.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1812_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1089\/ars.2010.3359","volume":"14","author":"G Zundorf","year":"2011","unstructured":"Zundorf G, Reiser G. Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection. Antioxid Redox Signal. 2011;14(7):1275\u201388.","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"1812_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neuron.2008.06.008","volume":"59","author":"KV Kuchibhotla","year":"2008","unstructured":"Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59(2):214\u201325.","journal-title":"Neuron"},{"issue":"4\u20135","key":"1812_CR32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.neuropharm.2010.07.012","volume":"59","author":"GA Krafft","year":"2010","unstructured":"Krafft GA, Klein WL. ADDls and the signaling web that leads to Alzheimer\u2019s disease. Neuropharmacology. 2010;59(4\u20135):230\u201342.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1812_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1471-4159.2001.00592.x","volume":"79","author":"MP Lambert","year":"2001","unstructured":"Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem. 2001;79(3):595\u2013605.","journal-title":"J Neurochem"},{"issue":"1","key":"1812_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s40478-018-0634-x","volume":"6","author":"C Julien","year":"2018","unstructured":"Julien C, Tomberlin C, Roberts CM, Akram A, Stein GH, Silverman MA, Link CD. In vivo induction of membrane damage by beta-amyloid peptide oligomers. Acta Neuropathol Commun. 2018;6(1):131.","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"1812_CR35","first-page":"3724","volume":"27","author":"D Zhang","year":"2017","unstructured":"Zhang D, Mably AJ, Walsh DM, Rowan MJ. Peripheral interventions enhancing brain glutamate homeostasis relieve amyloid beta- and TNFalpha- mediated synaptic plasticity disruption in the rat hippocampus. Cereb Cortex. 2017;27(7):3724\u201335.","journal-title":"Cereb Cortex"},{"issue":"4","key":"1812_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12640-012-9318-7","volume":"22","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Klein WL. Abeta oligomers-induced toxicity is attenuated in cells cultured with NbActiv4 medium. Neurotox Res. 2012;22(4):335\u201344.","journal-title":"Neurotox Res"},{"issue":"16","key":"1812_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26165091","volume":"26","author":"H Koike","year":"2021","unstructured":"Koike H, Iguchi Y, Sahashi K, Katsuno M. Significance of oligomeric and fibrillar species in amyloidosis: insights into pathophysiology and treatment. Molecules. 2021;26(16): 5091.","journal-title":"Molecules"},{"issue":"1","key":"1812_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L Soderberg","year":"2023","unstructured":"Soderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Moller C, Lannfelt L. Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics. 2023;20(1):195\u2013206.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1812_CR39","first-page":"255","volume":"4","author":"J O'Gorman","year":"2017","unstructured":"O\u2019Gorman J, Chiao P, Bussi\u00e8re T, von Rosenstiel P, Tian Y, Zhu Y, von Hehn C, Gheuens S, Skordos L, Chen T, Sandrock A. Clinical Development of Aducanumab, an Anti-A\u03b2 Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2017;4(4):255\u201363.","journal-title":"J Prev Alzheimers Dis."},{"issue":"6","key":"1812_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5008","volume":"33","author":"Y Han","year":"2024","unstructured":"Han Y, Desai AA, Zupancic JM, Smith MD, Tessier PM, Ruotolo BT. Native ion mobility-mass spectrometry reveals the binding mechanisms of anti-amyloid therapeutic antibodies. Protein Sci. 2024;33(6): e5008.","journal-title":"Protein Sci"},{"issue":"6","key":"1812_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1515\/revneuro-2017-0063","volume":"29","author":"AB Reiss","year":"2018","unstructured":"Reiss AB, Arain HA, Stecker MM, Siegart NM, Kasselman LJ. Amyloid toxicity in Alzheimer\u2019s disease. Rev Neurosci. 2018;29(6):613\u201327.","journal-title":"Rev Neurosci"},{"issue":"1","key":"1812_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00702-2","volume":"19","author":"M Calvo-Rodriguez","year":"2024","unstructured":"Calvo-Rodriguez M, Kharitonova EK, Snyder AC, Hou SS, Sanchez-Mico MV, Das S, Fan Z, Shirani H, Nilsson KPR, Serrano-Pozo A, Bacskai BJ. Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid beta aggregates in vivo in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2024;19(1): 6.","journal-title":"Mol Neurodegener"},{"key":"1812_CR43","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1007\/s12035-020-02064-4","volume":"57","author":"JS da Silva","year":"2020","unstructured":"da Silva JS, Nonose Y, Rohden F, Lukasewicz Ferreira PC, Fontella FU, Rocha A, Brochier AW, Apel RV, de Lima TM, Seminotti B, Amaral AU, Souza DO. Guanosine neuroprotection of presynaptic mitochondrial calcium homeostasis in a mouse study with amyloid-\u03b2 oligomers. Mol Neurobiol. 2020;57:4790\u2013809.","journal-title":"Mol Neurobiol"},{"issue":"23","key":"1812_CR44","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.1523\/JNEUROSCI.0482-13.2013","volume":"33","author":"CP Figueiredo","year":"2013","unstructured":"Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, De Felice FG, Ferreira ST. Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci. 2013;33(23):9626\u201334.","journal-title":"J Neurosci"},{"issue":"8","key":"1812_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837\u201342.","journal-title":"Nat Med"},{"issue":"35","key":"1812_CR46","doi-asserted-by":"publisher","first-page":"14745","DOI":"10.1073\/pnas.0905127106","volume":"106","author":"K Ono","year":"2009","unstructured":"Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A. 2009;106(35):14745\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1812_CR47","doi-asserted-by":"publisher","first-page":"51S","DOI":"10.1007\/BF02982587","volume":"12","author":"KL Viola","year":"2008","unstructured":"Viola KL, Velasco PT, Klein WL. Why Alzheimer\u2019s is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging. 2008;12(1):51S-S57.","journal-title":"J Nutr Health Aging"},{"issue":"19","key":"1812_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27196751","volume":"27","author":"C Song","year":"2022","unstructured":"Song C, Zhang T, Zhang Y. Conformational essentials responsible for neurotoxicity of A\u03b242 aggregates revealed by antibodies against oligomeric A\u03b242. Molecules. 2022;27(19): 6751.","journal-title":"Molecules"},{"issue":"19","key":"1812_CR49","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1038\/emboj.2010.211","volume":"29","author":"I Kuperstein","year":"2010","unstructured":"Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D\u2019hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer\u2019s disease A\u03b2 peptides is induced by small changes in the A\u03b242 to A\u03b240 ratio. The EMBO journal. 2010;29(19):3408\u201320.","journal-title":"The EMBO journal."},{"issue":"6","key":"1812_CR50","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nprot.2010.72","volume":"5","author":"A Jan","year":"2010","unstructured":"Jan A, Hartley DM, Lashuel HA. Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer\u2019s disease research. Nat Protoc. 2010;5(6):1186\u2013209.","journal-title":"Nat Protoc"},{"issue":"51","key":"1812_CR51","doi-asserted-by":"publisher","first-page":"15157","DOI":"10.1021\/bi061850f","volume":"45","author":"RW Hepler","year":"2006","unstructured":"Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry. 2006;45(51):15157\u201367.","journal-title":"Biochemistry"},{"issue":"52","key":"1812_CR52","doi-asserted-by":"publisher","first-page":"37104","DOI":"10.1074\/jbc.M113.513432","volume":"288","author":"CS Gr\u00fcning","year":"2013","unstructured":"Gr\u00fcning CS, Klinker S, Wolff M, Schneider M, Toks\u00f6z K, Klein AN, Nagel-Steger L, Willbold D, Hoyer W. The off-rate of monomers dissociating from amyloid-\u03b2 protofibrils. J Biol Chem. 2013;288(52):37104\u201311.","journal-title":"J Biol Chem"},{"issue":"11","key":"1812_CR53","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95(11):6448\u201353.>","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"1812_CR54","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","volume":"29","author":"K Yamada","year":"2009","unstructured":"Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci. 2009;29(36):11393\u20138.","journal-title":"J Neurosci"},{"issue":"5","key":"1812_CR55","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, Mcdonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76(5):908\u201320.","journal-title":"Neuron"},{"issue":"1","key":"1812_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00292-3","volume":"11","author":"C Song","year":"2022","unstructured":"Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H, Chen H. Immunotherapy for Alzheimer\u2019s disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022;11(1): 18.","journal-title":"Transl Neurodegener"},{"issue":"19","key":"1812_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914499","volume":"24","author":"E Fedele","year":"2023","unstructured":"Fedele E. Anti-amyloid therapies for Alzheimer\u2019s disease and the amyloid cascade hypothesis. Int J Mol Sci. 2023;24(19): 14499.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1812_CR58","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","volume":"20","author":"G Yadollahikhales","year":"2023","unstructured":"Yadollahikhales G, Rojas JC. Anti-amyloid immunotherapies for Alzheimer\u2019s disease: a 2023 clinical update. Neurotherapeutics. 2023;20(4):914\u201331.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1812_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0338-2","volume":"10","author":"GJ Pagnier","year":"2018","unstructured":"Pagnier GJ, Kastanenka KV, Sohn M, Choi S, Choi SH, Soh H, Bacskai BJ. Novel botanical drug DA-9803 prevents deficits in Alzheimer\u2019s mouse models. Alzheimers Res Ther. 2018;10(1): 11.","journal-title":"Alzheimers Res Ther"},{"key":"1812_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","volume":"143","author":"S Gustafsson","year":"2018","unstructured":"Gustafsson S, Gustavsson T, Roshanbin S, Hultqvist G, Hammarlund-Udenaes M, Sehlin D, Syvanen S. Blood-brain barrier integrity in a mouse model of Alzheimer\u2019s disease with or without acute 3D6 immunotherapy. Neuropharmacology. 2018;143:1\u20139.","journal-title":"Neuropharmacology"},{"issue":"9","key":"1812_CR61","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/jpp\/rgae066","volume":"76","author":"A Azargoonjahromi","year":"2024","unstructured":"Azargoonjahromi A. Immunotherapy in Alzheimer\u2019s disease: focusing on the efficacy of gantenerumab on amyloid-\u03b2 clearance and cognitive decline. J Pharm Pharmacol.\u00a0 2024;76(9):1115\u201331.","journal-title":"J Pharm Pharmacol.\u00a0"},{"issue":"1","key":"1812_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1): 95.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"1812_CR63","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, Van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS, Alzheimer\u2019s S Team. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389(12):1096\u2013107.","journal-title":"N Engl J Med"},{"key":"1812_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6771","volume":"355","author":"DG Le Couteur","year":"2016","unstructured":"Le Couteur DG, Hunter S, Brayne C. Solanezumab and the amyloid hypothesis for Alzheimer\u2019s disease. BMJ. 2016;355:i6771.","journal-title":"BMJ"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01812-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:36:18Z","timestamp":1757342178000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01812-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01812-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}